Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Maven Securities LTD

Maven Securities LTD decreased its holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 50.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 25,000 shares of the company’s stock after selling 25,000 shares during the period. Maven Securities LTD’s holdings in Amylyx Pharmaceuticals were worth $449,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMLX. BlackRock Inc. purchased a new stake in Amylyx Pharmaceuticals during the second quarter worth approximately $158,534,000. Jupiter Topco LLC purchased a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter valued at $94,014,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Amylyx Pharmaceuticals by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after acquiring an additional 3,102,395 shares in the last quarter. Millennium Management LLC lifted its holdings in shares of Amylyx Pharmaceuticals by 418.6% during the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after acquiring an additional 2,487,617 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its position in Amylyx Pharmaceuticals by 76.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock worth $53,992,000 after purchasing an additional 1,929,639 shares during the period. 95.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Guggenheim boosted their price objective on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, August 27th. HC Wainwright upped their target price on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Robert W. Baird increased their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. Finally, Citigroup increased their target price on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $36.50.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of Amylyx Pharmaceuticals stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the sale, the insider directly owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. The trade was a 7.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.90% of the stock is owned by corporate insiders.

Amylyx Pharmaceuticals Trading Down 0.6%

Shares of AMLX stock opened at $33.88 on Wednesday. The company has a market capitalization of $3.77 billion, a PE ratio of -23.69 and a beta of -0.13. The firm has a fifty day simple moving average of $24.86 and a 200-day simple moving average of $18.49. Amylyx Pharmaceuticals, Inc. has a twelve month low of $10.37 and a twelve month high of $41.14.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03). Equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current year.

Amylyx Pharmaceuticals Profile